The National Cancer Institute (NCI) is offering this grant to advance cancer etiology and early detection biomarker research. This funding encourages proposals leveraging the unique NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial biorepository. The PLCO Biorepository provides high-quality, prospectively collected pre-diagnostic blood samples and buccal cells, complete with demographic, lifestyle, and clinical data. This grant is for the purpose of supporting wide-ranging cancer research, encompassing biochemical/genetic analyses of cancer risk and discovery/validation of early detection biomarkers. Projects must strictly utilize and capitalize on PLCO biospecimens for eligibility.
Opportunity ID: 357307
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-248 |
| Funding Opportunity Title: | Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 21, 2024 |
| Last Updated Date: | Nov 21, 2024 |
| Original Closing Date for Applications: | Oct 08, 2027 |
| Current Closing Date for Applications: | Oct 08, 2027 |
| Archive Date: | Nov 13, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities Small businesses County governments City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) State governments Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Private institutions of higher education Special district governments Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-248.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357307 Full Announcement-PAR-25-248 -> PAR-25-248-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288885 | Jan 10, 2025 | Oct 08, 2027 | View |
Package 1
Mandatory forms
357307 RR_SF424_5_0-5.0.pdf
357307 PHS398_CoverPageSupplement_5_0-5.0.pdf
357307 RR_OtherProjectInfo_1_4-1.4.pdf
357307 PerformanceSite_4_0-4.0.pdf
357307 RR_KeyPersonExpanded_4_0-4.0.pdf
357307 PHS398_ResearchPlan_5_0-5.0.pdf
357307 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357307 RR_Budget_3_0-3.0.pdf
357307 RR_SubawardBudget30_3_0-3.0.pdf
357307 PHS398_ModularBudget_1_2-1.2.pdf
357307 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
